Mark Rolfe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark Rolfe has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Andy Christoforou
Bristol Myers Squibb, USA, California, United States
12 shared publications - Celia Fontanillo
Predictive Sciences, Bristol Myers Squibb, San Diego, California
12 shared publications - Daniel W. Pierce
Protein Homeostasis (PH) Thematic Research Center (TRC), Bristol Myers Squibb, San Diego, California
12 shared publications - Neil Bence
Bristol Myers Squibb, San Diego, California, United States
12 shared publications - Rama Krishna Narla
Bristol Myers Squibb, San Diego, California, United States
12 shared publications - Brandon Toyama
Bristol Myers Squibb, San Diego, California
9 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-16 from Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma
Supplementary Table 1: Atomic modelling, refinement, and validation statistics. Supplementary Table 2: Cryo-EM data collection and image analysis. Supplementary Table 3: Lymphoma cell lines evaluated in golcadomide study. Supplementary Table 4: Densitometry-based quantification of protein expression of selected markers within DLBCL cell line panel. Supplementary Table 5: Summary of the IC50 and proliferation AUC of lymphoma cell lines treated with golcadomide or other compounds. Supplementary Table 6: Genes with a significant modulation and temporal pattern in the golcadomide sensitive models. Supplementary Table 7: Pathway analysis of genes enriched for interferon signalling and immune system. Supplementary Table 8: BioMAP diversity plus panel result of golcadomide. Supplementary Table 9: Tissue distribution profile in rats treated with 10 mg/kg golcadomide. Supplementary Table 10: Plasma and brain pharmacokinetics of golcadomide in the OCI-Ly10 central nervous system lymphoma model. Supplementary Table 11. List of golcadomide enriched or depleted genes (FDR <= 0.05) in SU-DHL-4 CRISPR screen. Supplemental Table 12: Summary of apoptosis and proliferation of lymphoma cell lines treated with single agent or in combination with golcadomide. Supplementary Table 13: Summary of synergy score and max synergy area from the golcadomide combination therapies. Supplementary Table 14: Gene enrichment scores of FACS competition assays in DLBCL cell lines with golcadomide treatment. Supplementary Table 15: List of antibodies. Supplementary Table 16: List of genes and guide sequences used for CRISPR-Cas9 knockout assay and genome wide CRISPR screen.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-16 from Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma
Supplementary Table 1: Atomic modelling, refinement, and validation statistics. Supplementary Table 2: Cryo-EM data collection and image analysis. Supplementary Table 3: Lymphoma cell lines evaluated in golcadomide study. Supplementary Table 4: Densitometry-based quantification of protein expression of selected markers within DLBCL cell line panel. Supplementary Table 5: Summary of the IC50 and proliferation AUC of lymphoma cell lines treated with golcadomide or other compounds. Supplementary Table 6: Genes with a significant modulation and temporal pattern in the golcadomide sensitive models. Supplementary Table 7: Pathway analysis of genes enriched for interferon signalling and immune system. Supplementary Table 8: BioMAP diversity plus panel result of golcadomide. Supplementary Table 9: Tissue distribution profile in rats treated with 10 mg/kg golcadomide. Supplementary Table 10: Plasma and brain pharmacokinetics of golcadomide in the OCI-Ly10 central nervous system lymphoma model. Supplementary Table 11. List of golcadomide enriched or depleted genes (FDR <= 0.05) in SU-DHL-4 CRISPR screen. Supplemental Table 12: Summary of apoptosis and proliferation of lymphoma cell lines treated with single agent or in combination with golcadomide. Supplementary Table 13: Summary of synergy score and max synergy area from the golcadomide combination therapies. Supplementary Table 14: Gene enrichment scores of FACS competition assays in DLBCL cell lines with golcadomide treatment. Supplementary Table 15: List of antibodies. Supplementary Table 16: List of genes and guide sequences used for CRISPR-Cas9 knockout assay and genome wide CRISPR screen.
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma
Supplementary Fig. 1. Golcadomide induced transition from CRBNopen to CRBNclosed for efficient recruitment and degradaion. Supplementary Fig. 2. Antiproliferative effect of golcadomide is mediated via CRBN-based IKZF1/3 degradation. Supplementary Fig. 3. Golcadomide is broadly active with potent cell autonomous antiproliferative activity. Supplementary Fig. 4. Antiproliferative effect of golcadomide is mediated via CRBN based IKZF1/3 degradation. Supplementary Fig. 5. Golcadomide demonstrated minimal broad cytotoxicity and reversible effects on neutrophil maturation. Supplementary Fig. 6. Golcadomide stimulated immune activation, reversed T cell exhaustion, and exhibited potent antitumor synergy with rituximab. Supplementary Fig. 7. Overview of different treatment conditions and technical replicates in the CRISPR screen. Supplementary Fig. 8. CRISPR screen identified genes and pathways that exacerbated or attenuated antiproliferative effects of golcadomide in SU-DHL-4 upon inactivation. Supplementary Fig. 9. KO of PRC2 complex components enhanced cell antiproliferation by golcadomide. Supplementary Fig. 10. Apoptosis induction is linked to the antiproliferative effects of golcadomide. Supplementary Fig. 11. NF-κB hyperactivation reduced golcadomide-induced DLBCL cell apoptosis. Supplementary Fig. 12. XPO1 inhibitor enhances antiproliferative effects of golcadomide. Supplementary Fig. 13. AMBRA1 knockout renders resistance to golcadomide via cyclin D3/CDK4/6/Rb axis in DLBCL. Supplementary Fig. 14. KCTD5 ameliorated the antiproliferative effects of golcadomide via GNG5. Supplementary Fig. 15. Chemical synthesis of golcadomide. Supplementary Fig. 16. Representative gating strategies for flow cytometry-based assays.
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma
Supplementary Fig. 1. Golcadomide induced transition from CRBNopen to CRBNclosed for efficient recruitment and degradaion. Supplementary Fig. 2. Antiproliferative effect of golcadomide is mediated via CRBN-based IKZF1/3 degradation. Supplementary Fig. 3. Golcadomide is broadly active with potent cell autonomous antiproliferative activity. Supplementary Fig. 4. Antiproliferative effect of golcadomide is mediated via CRBN based IKZF1/3 degradation. Supplementary Fig. 5. Golcadomide demonstrated minimal broad cytotoxicity and reversible effects on neutrophil maturation. Supplementary Fig. 6. Golcadomide stimulated immune activation, reversed T cell exhaustion, and exhibited potent antitumor synergy with rituximab. Supplementary Fig. 7. Overview of different treatment conditions and technical replicates in the CRISPR screen. Supplementary Fig. 8. CRISPR screen identified genes and pathways that exacerbated or attenuated antiproliferative effects of golcadomide in SU-DHL-4 upon inactivation. Supplementary Fig. 9. KO of PRC2 complex components enhanced cell antiproliferation by golcadomide. Supplementary Fig. 10. Apoptosis induction is linked to the antiproliferative effects of golcadomide. Supplementary Fig. 11. NF-κB hyperactivation reduced golcadomide-induced DLBCL cell apoptosis. Supplementary Fig. 12. XPO1 inhibitor enhances antiproliferative effects of golcadomide. Supplementary Fig. 13. AMBRA1 knockout renders resistance to golcadomide via cyclin D3/CDK4/6/Rb axis in DLBCL. Supplementary Fig. 14. KCTD5 ameliorated the antiproliferative effects of golcadomide via GNG5. Supplementary Fig. 15. Chemical synthesis of golcadomide. Supplementary Fig. 16. Representative gating strategies for flow cytometry-based assays.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Tables 1 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
Supplementary tables as described in main text
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTables 1 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
Supplementary tables as described in main text
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
Purpose:BMS-986365, a heterobifunctional androgen receptor (AR) ligand-directed degrader, was designed as a potent cereblon-dependent degrader and competitive antagonist of the AR to overcome resistance to AR pathway inhibition (ARPI) in metastatic prostate cancer.Experimental Design:The in vitro impact of BMS-986365–induced AR degradation on AR activity and prostate cancer cell proliferation was evaluated. Intrinsic agonistic and antagonist activities of BMS-986365 were assessed. The in vivo antitumor activity of BMS-986365 was compared with enzalutamide in multiple cell line– or patient-derived prostate cancer models.Results:BMS-986365 is a potent, rapid, and selective degrader of AR wild-type (WT) and most of the clinically relevant mutants. Degradation of both WT and mutant AR is the key driver of BMS-986365 efficacy, with additional antagonism of residual AR activity enabled through occupancy of its ligand-binding domain. Compared with enzalutamide, BMS-986365 more efficiently inhibits AR target gene transcription and AR-dependent proliferation of prostate cancer cell lines. Whereas enzalutamide increased AR protein in metastatic castration-resistant prostate cancer (CRPC) models, BMS-986365 maintained low levels of AR protein despite increased AR transcript levels. In vivo, BMS-986365 demonstrated on-target activity, degrading AR, suppressing AR signaling, and inhibiting growth in validated cell line– and patient-derived xenograft models of castration-sensitive prostate cancer and advanced and/or therapy-resistant CRPC. Clinically, BMS-986365 reduced PSA in patients with metastatic CRPC after ARPI, including patients with WT AR.Conclusions:The preclinical observations, coupled with clinical data, strongly support the potential for BMS-986365 to overcome ARPI-resistant disease regardless of AR mutational status. These findings establish BMS-986365 as a first-in-class dual AR degrader and competitive antagonist, likely to emerge as an important tool in the armamentarium to treat prostate cancer.See related commentary by Nyquist and Nelson, p. 13
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
Purpose:BMS-986365, a heterobifunctional androgen receptor (AR) ligand-directed degrader, was designed as a potent cereblon-dependent degrader and competitive antagonist of the AR to overcome resistance to AR pathway inhibition (ARPI) in metastatic prostate cancer.Experimental Design:The in vitro impact of BMS-986365–induced AR degradation on AR activity and prostate cancer cell proliferation was evaluated. Intrinsic agonistic and antagonist activities of BMS-986365 were assessed. The in vivo antitumor activity of BMS-986365 was compared with enzalutamide in multiple cell line– or patient-derived prostate cancer models.Results:BMS-986365 is a potent, rapid, and selective degrader of AR wild-type (WT) and most of the clinically relevant mutants. Degradation of both WT and mutant AR is the key driver of BMS-986365 efficacy, with additional antagonism of residual AR activity enabled through occupancy of its ligand-binding domain. Compared with enzalutamide, BMS-986365 more efficiently inhibits AR target gene transcription and AR-dependent proliferation of prostate cancer cell lines. Whereas enzalutamide increased AR protein in metastatic castration-resistant prostate cancer (CRPC) models, BMS-986365 maintained low levels of AR protein despite increased AR transcript levels. In vivo, BMS-986365 demonstrated on-target activity, degrading AR, suppressing AR signaling, and inhibiting growth in validated cell line– and patient-derived xenograft models of castration-sensitive prostate cancer and advanced and/or therapy-resistant CRPC. Clinically, BMS-986365 reduced PSA in patients with metastatic CRPC after ARPI, including patients with WT AR.Conclusions:The preclinical observations, coupled with clinical data, strongly support the potential for BMS-986365 to overcome ARPI-resistant disease regardless of AR mutational status. These findings establish BMS-986365 as a first-in-class dual AR degrader and competitive antagonist, likely to emerge as an important tool in the armamentarium to treat prostate cancer.See related commentary by Nyquist and Nelson, p. 13
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
Discovery and synthesis of BMS-986365
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
Discovery and synthesis of BMS-986365
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
Dual mechanism of action of BMS-986365 is important for its anti-proliferative effect
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
Dual mechanism of action of BMS-986365 is important for its anti-proliferative effect
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
BMS-986365 overcomes resistance to ARPIs due to an adaptative mechanism in vitro.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
BMS-986365 overcomes resistance to ARPIs due to an adaptative mechanism in vitro.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
BMS-986365 shows robust anti-tumor activity in multiple prostate cancer CDX and PDX models
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
BMS-986365 shows robust anti-tumor activity in multiple prostate cancer CDX and PDX models
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
BMS-986365 binds and selectively degrades AR
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer
BMS-986365 binds and selectively degrades AR